Table 5

Associations of breast cancer with combined IGF and steroid hormones among postmenopausal womena

VariableIGF-IIGF-IIIGFBP-3
No.bOR (95% CI)No.OR (95% CI)No.OR (95% CI)
Testosterone       
 Low/lowc 35/24 1.00 30/21 1.00 32/20 1.00 
 High/low 30/31 1.67 (0.78–3.61) 35/35 1.35 (0.60–3.07) 33/29 1.63 (0.71–3.72) 
 Low/high 30/23 1.05 (0.46–2.41) 35/26 1.18 (0.39–3.54) 33/27 1.31 (0.55–3.12) 
 High/high 35/48 2.15 (1.02–4.50) 30/44 3.06 (1.10–8.53) 32/50 2.68 (1.18–6.06) 
Estrone       
 Low/low 33/22 1.00 25/18 1.00 39/22 1.00 
 High/low 31/32 1.84 (0.86–3.97) 38/37 1.71 (0.67–4.36) 26/27 2.13 (0.94–4.83) 
 Low/high 31/27 1.22 (0.54–2.77) 39/31 1.48 (0.47–4.70) 25/27 1.70 (0.75–3.88) 
 High/high 33/44 2.19 (1.06–4.56) 26/39 2.77 (1.00–7.63) 38/49 2.63 (1.21–5.73) 
Estradiol       
 Low/low 35/22 1.00 22/20 1.00 41/27 1.00 
 High/low 30/33 1.88 (0.73–4.82) 43/36 0.99 (0.39–2.58) 24/22 1.62 (0.62–4.25) 
 Low/high 29/35 1.93 (0.84–4.43) 42/37 1.28 (0.43–3.82) 23/30 1.77 (0.86–3.61) 
 High/high 36/36 1.67 (0.70–3.98) 23/33 2.24 (0.74–6.81) 42/47 2.23 (0.84–5.93) 
Estrone-S       
 Low/low 30/23 1.00 43/29 1.00 20/17 1.00 
 High/low 35/32 1.30 (0.60–2.82) 22/27 2.02 (0.87–4.70) 45/32 0.63 (0.25–1.58) 
 Low/high 35/32 1.27 (0.60–2.69) 22/26 2.62 (0.96–7.17) 45/38 0.80 (0.34–1.88) 
 High/high 30/39 1.72 (0.78–3.79) 43/44 2.33 (0.86–6.29) 20/39 1.78 (0.74–4.25) 
DHEA-S       
 Low/low 39/28 1.00 35/25 1.00 34/21 1.00 
 High/low 26/27 1.50 (0.74–3.04) 30/31 1.41 (0.67–2.96) 31/28 1.63 (0.73–3.62) 
 Low/high 26/24 1.37 (0.65–2.89) 30/27 1.79 (0.64–4.97) 31/31 1.81 (0.79–4.15) 
 High/high 39/47 1.72 (0.84–3.50) 35/43 2.47 (0.93–6.57) 34/46 2.07 (0.99–4.35) 
VariableIGF-IIGF-IIIGFBP-3
No.bOR (95% CI)No.OR (95% CI)No.OR (95% CI)
Testosterone       
 Low/lowc 35/24 1.00 30/21 1.00 32/20 1.00 
 High/low 30/31 1.67 (0.78–3.61) 35/35 1.35 (0.60–3.07) 33/29 1.63 (0.71–3.72) 
 Low/high 30/23 1.05 (0.46–2.41) 35/26 1.18 (0.39–3.54) 33/27 1.31 (0.55–3.12) 
 High/high 35/48 2.15 (1.02–4.50) 30/44 3.06 (1.10–8.53) 32/50 2.68 (1.18–6.06) 
Estrone       
 Low/low 33/22 1.00 25/18 1.00 39/22 1.00 
 High/low 31/32 1.84 (0.86–3.97) 38/37 1.71 (0.67–4.36) 26/27 2.13 (0.94–4.83) 
 Low/high 31/27 1.22 (0.54–2.77) 39/31 1.48 (0.47–4.70) 25/27 1.70 (0.75–3.88) 
 High/high 33/44 2.19 (1.06–4.56) 26/39 2.77 (1.00–7.63) 38/49 2.63 (1.21–5.73) 
Estradiol       
 Low/low 35/22 1.00 22/20 1.00 41/27 1.00 
 High/low 30/33 1.88 (0.73–4.82) 43/36 0.99 (0.39–2.58) 24/22 1.62 (0.62–4.25) 
 Low/high 29/35 1.93 (0.84–4.43) 42/37 1.28 (0.43–3.82) 23/30 1.77 (0.86–3.61) 
 High/high 36/36 1.67 (0.70–3.98) 23/33 2.24 (0.74–6.81) 42/47 2.23 (0.84–5.93) 
Estrone-S       
 Low/low 30/23 1.00 43/29 1.00 20/17 1.00 
 High/low 35/32 1.30 (0.60–2.82) 22/27 2.02 (0.87–4.70) 45/32 0.63 (0.25–1.58) 
 Low/high 35/32 1.27 (0.60–2.69) 22/26 2.62 (0.96–7.17) 45/38 0.80 (0.34–1.88) 
 High/high 30/39 1.72 (0.78–3.79) 43/44 2.33 (0.86–6.29) 20/39 1.78 (0.74–4.25) 
DHEA-S       
 Low/low 39/28 1.00 35/25 1.00 34/21 1.00 
 High/low 26/27 1.50 (0.74–3.04) 30/31 1.41 (0.67–2.96) 31/28 1.63 (0.73–3.62) 
 Low/high 26/24 1.37 (0.65–2.89) 30/27 1.79 (0.64–4.97) 31/31 1.81 (0.79–4.15) 
 High/high 39/47 1.72 (0.84–3.50) 35/43 2.47 (0.93–6.57) 34/46 2.07 (0.99–4.35) 
a

Unadjusted conditional logistic regression analysis.

b

Number of control versus number of case.

c

Low/low, low steroids and low IGF-I or IGFBP-3; High/low, high steroids and low IGF-I or IGFBP-3; Low/high, low steroids and high IGF-I or IGFBP-3; High/high, high steroids and high IGF-I or IGFBP-3; Low, lower than median; High, higher than or equal to median.

Close Modal

or Create an Account

Close Modal
Close Modal